ProCE Banner Activity

CE / CME

Latest Advances in Gastroesophageal Cancers: Community Workshops for the Multidisciplinary Team

Video

On-demand webcast of an expert-led webinar on managing gastroesophageal cancers with targeted and immunotherapies.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 19, 2023

Expiration: June 18, 2024

Share

Faculty

Jaffer A. Ajani

Jaffer A. Ajani, MD

Professor 
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

David H. Ilson

David H. Ilson, MD, PhD

Professor
Department of Medicine
Weill Cornell Medical College
Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Anwaar Saeed

Anwaar Saeed, MD

Associate Professor 
Chief of GI
Division of Hematology and Oncology
Univeristy of Pittsburgh Medical Center & UPMC Hillman Cancer Center
Pennsylvania, Pittsburgh

 

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This program is intended for oncologists, nurses, pharmacists and other healthcare professionals involved in the treatment of patients with gastroesophageal cancers.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, competence of community care teams in integrating the available clinical data, guidelines, and expert recommendations into the care of their patients with gastroesophageal cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify appropriate patients with completely resected esophageal or GEJ cancer who are candidates for adjuvant immunotherapy 

  • Plan frontline immune checkpoint inhibitor–based therapy for appropriate patients based on recent clinical data and current indications in esophageal squamous cell carcinoma

  • Develop optimal sequencing of agents for patients with HER2-positive gastric/GEJ cancer 

  • Incorporate histology-agnostic targeted therapy into treatment plans using newly approved indications

  • Manage treatment-related symptoms for patient with gastric, GEJ, or esophageal squamous cell carcinoma

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Jaffer A. Ajani, MD

Professor 
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jaffer Ajani, MD: advisor: Acrotech, Amgen, Arcus, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol-Myers Squibb, Dava, Daiichi Sankyo, FivePrime, Geneos, Gilead, GRAIL, Innovent, Merck, Merck Serono, More, Novartis, OncLive, Oncotherics, Servier, Taiho, Vaccinogen, Zymeworks.

David H. Ilson, MD, PhD

Professor
Department of Medicine
Weill Cornell Medical College
Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

David Ilson, MD, PhD: consultant/advisor/speaker: Amgen, Astellas, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Lilly, Merck, Roche, Taiho.

Anwaar Saeed, MD

Associate Professor 
Chief of GI
Division of Hematology and Oncology
Univeristy of Pittsburgh Medical Center & UPMC Hillman Cancer Center
Pennsylvania, Pittsburgh

 

Anwaar Saeed, MD: consultant/advisor/speaker: Bristol-Myers Squib, Exelixis; researcher: Actuate Therapeutics, AstraZeneca, Bristol-Myers Squib, Clovis, Dragonfly Therapeutics, Exelixis, Incyte, Innovent Biologics, KAHR Medical, Merck.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 19, 2023, through June 18, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hours.

 

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-172-H01-P
Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.